Liver/Biliary Disorders News

Recently the European Association for the Study of the Liver updated its clinical practice guidelines for management of hepatocellular carcinoma.

Researchers recommended a third SARS-CoV-2 vaccination dose for liver transplant recipients and patients with cirrhosis who have a low or absent serological response.

Regarding cardiovascular mortality, results published in the Scandinavian Journal of Gastroenterology demonstrated a negative interaction between fatty liver disease and hypertension in nondiabetic men.

A cohort of veterans with cirrhosis who received the mRNA COVID-19 vaccine had a delayed and modest decrease in infection, with an excellent decrease in hospitalizations or death.

Mitochondrial mechanisms of toxicity may be an important cause of drug-induced liver injury, according to a study published in Acta Pharmaceutica Sinica B.

The International Hepato-Pancreato-Biliary Association established consensus guidelines for liver transplantation among patients with nonresectable colorectal liver metastases.

In a cohort of predominantly men with primary biliary cholangitis with cirrhosis, ursodeoxycholic acid response correlated with a decrease in decompensation, all-cause, and liver-related death or transplantation, according to study results.

Solid organ transplant recipients, including liver transplant recipients, are likely at an increased risk for severe COVID-19, therefore researchers recommended priority vaccination status for patients’ pre-transplantation.

High-sensitivity cardiac troponin may be used as a marker for predicting coronary artery disease risk in patients with nonalcoholic fatty liver disease, according to a study published in Clinical Gastroenterology and Hepatology.

Women who only accessed deceased donor liver transplant had worse outcomes than men independent of existing liver disease but access to living donor LT may bridge this disparity gap women face.